(Q41138757)

27 September 2017

1 reference

title

Will angiotensin II receptor antagonists be renoprotective in humans? (English)

1 reference

27 September 2017

Ichikawa I

1

1 reference

27 September 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

27 September 2017

1 reference

27 September 2017

volume

50

1 reference

27 September 2017

issue

2

1 reference

27 September 2017

page(s)

684-692

1 reference

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Effects of oral adsorbent in the rat model of chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Proteinuria--a direct cause of renal morbidity?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Tubulointerstitial damage in glomerular diseases: Its role in the progression of renal damage

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

A mononuclear cell component in experimental immunological glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

The effect of acute angiotensin II blockade on renal function in rats with reduced renal mass.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Developmental expression of renal angiotensin II receptor genes in the mouse.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Developmental changes in angiotensin II receptor subtypes and AT1 receptor mRNA in rat kidney.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.365

7 January 2021

Identifiers

DOI

10.1038/KI.1996.365

1 reference

27 September 2017

1 reference